# ALSYMPCA (NCT00699751)

> A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT00699751
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Bayer
- Conditions: Hormone Refractory Prostate Cancer; Bone Metastases
- Interventions: Radium-223 dichloride (Xofigo, BAY88-8223); Placebo; Best standard of care (BSoC)
- Enrollment: 921
- Primary outcome: Overall Survival

## Commentary we found

- YouTube: 26
- Podcasts: 16
- X threads: 4

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=alsympca-nct00699751

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT00699751", "email": "<work email>"}; the inbox owner confirms by the emailed link.